Cardiovascular outcomes of vildagliptin in patients with type 2 diabetes mellitus after acute coronary syndrome or acute ischemic stroke

AIMS/INTRODUCTION: The cardiovascular (CV) outcomes of vildagliptin – a dipeptidyl peptidase‐4 inhibitor – in patients with type 2 diabetes mellitus after acute coronary syndrome or acute ischemic stroke are unclear. MATERIALS AND METHODS: We analyzed data from the Taiwan National Health Insurance R...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Dong‐Yi, Li, Yan‐Rong, Mao, Chun‐Tai, Tseng, Chi‐Nan, Hsieh, I‐Chang, Hung, Ming‐Jui, Chu, Pao‐Hsien, Wang, Chao‐Hung, Wen, Ming‐Shien, Cherng, Wen‐Jin, Chen, Tien‐Hsing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944835/
https://www.ncbi.nlm.nih.gov/pubmed/31115964
http://dx.doi.org/10.1111/jdi.13078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944835/
https://www.ncbi.nlm.nih.gov/pubmed/31115964
http://dx.doi.org/10.1111/jdi.13078

Ejemplares similares